In a trademark dispute between Zuneca Pharmaceutical and Natrapharm, Inc., the Supreme Court affirmed that under the Intellectual Property Code (IP Code), trademark ownership is acquired through registration, not prior use. This means that the first party to register a trademark in good faith generally has superior rights, even if another party used the mark earlier. However, the Court also held that a prior user in good faith may continue using their mark even after another party registers it, but this right is tied to their existing business.
Whose Brand Is It Anyway? Zuneca vs. Natrapharm’s Trademark Showdown
Zuneca Pharmaceutical, engaged in importing and selling medicines since 1999, used the brand name “ZYNAPS” for its carbamazepine drug. Natrapharm, on the other hand, registered the trademark “ZYNAPSE” in 2007 for its citicoline product. Natrapharm then sued Zuneca for trademark infringement, arguing that “ZYNAPS” was confusingly similar to its registered mark. Zuneca countered that it had been using “ZYNAPS” since 2004, predating Natrapharm’s registration, and that Natrapharm acted in bad faith by registering a confusingly similar mark despite knowing of Zuneca’s prior use. The central legal question before the Supreme Court was: In a trademark dispute, does prior registration trump prior use?
The Supreme Court held that under the IP Code, ownership of a trademark is acquired through registration, provided the registration is made in good faith. This principle is enshrined in Section 122 of the IP Code, which states, “The rights in a mark shall be acquired through registration made validly in accordance with the provisions of this law.” This marked a shift from the previous Trademark Law, which prioritized prior use in determining trademark ownership. The Court emphasized that the intent of the lawmakers was to abandon the rule that ownership of a mark is acquired through use, as evidenced by the legislative history of the IP Code.
The Court found that Natrapharm had registered its trademark in good faith, as there was no evidence that it knew of Zuneca’s prior use of “ZYNAPS” at the time of registration. Consequently, Natrapharm, as the registered owner of “ZYNAPSE,” had the right to prevent others from using confusingly similar marks for related goods or services. However, the Court also recognized an exception: Section 159.1 of the IP Code states that a registered mark has no effect against any person who, in good faith, before the filing date, was using the mark for the purposes of his business or enterprise.
In effect, this exception protects prior users who, in good faith, had already been using a mark before someone else registered it. To clarify, Section 159.1 of the IP Code states:
SECTION 159. Limitations to Actions for Infringement. – Notwithstanding any other provision of this Act, the remedies given to the owner of a right infringed under this Act shall be limited as follows:
159.1. Notwithstanding the provisions of Section 155 hereof, a registered mark shall have no effect against any person who, in good faith, before the filing date or the priority date, was using the mark for the purposes of his business or enterprise: Provided, That his right may only be transferred or assigned together with his enterprise or business or with that part of his enterprise or business in which the mark is used.
This section serves as a limitation on the rights conferred by trademark registration, acknowledging the equities of prior users who have built goodwill around a mark before registration occurs. As the Court elaborated, this section should not be interpreted as merely exempting prior use before the registration date but as protecting the prior user’s right to continue using the mark, as long as it remains connected to their original business.
Building on this principle, the Court ruled that Zuneca, as a prior user in good faith of the “ZYNAPS” mark, was protected from liability for trademark infringement. This protection, however, was not without limits. Zuneca’s right to use “ZYNAPS” was tied to its existing business, and it could not transfer or assign the mark independently of that business. The decision acknowledged the potential for confusion arising from the concurrent use of similar marks for pharmaceutical products but emphasized the importance of adhering to the provisions of the IP Code while also ordering the parties to prominently display information about their products’ uses on their packaging to mitigate confusion.
The Supreme Court underscored the importance of complying with the Generics Act of 1988, as amended, which mandates the use of generic names in prescriptions. The intent is to help protect the public even where brand names may cause confusion. The Court further directed the Food and Drug Administration to monitor and regulate drug names to prevent the concurrent use of confusingly similar names for medicines. This part of the decision recognized the state’s duty to “protect and promote the right to health of the people and instill health consciousness among them.”
In effect, the Zuneca v. Natrapharm ruling clarifies the interplay between registration and use in Philippine trademark law, affirming the primacy of registration while carving out protections for prior users who have acted in good faith. While a registrant has rights to a mark, a good faith prior user of a confusingly similar mark is given some leeway. This is a carefully balanced approach intended to protect the rights of legitimate businesses while also acknowledging prior investments made in building brand recognition.
FAQs
What was the key issue in this case? | The key issue was to determine the prevailing party in a trademark dispute and whether trademark infringement existed, necessitating a ruling on the acquisition of ownership of marks by both parties. |
How does the Intellectual Property Code define trademark ownership? | Under the IP Code, trademark ownership is primarily acquired through registration made validly in accordance with the provisions of the law, not through prior use. |
What is the “first-to-file” rule? | The “first-to-file” rule means that the first party to register a trademark generally has superior rights, even if another party used the mark earlier. |
Does prior use have any relevance under the IP Code? | Yes, Section 159.1 of the IP Code protects a prior user in good faith, allowing them to continue using their mark even after another party registers it, provided the use is tied to their existing business. |
What is bad faith in trademark registration? | Bad faith in trademark registration means that the applicant knew of a prior creation, use, or registration by another of an identical or similar trademark. |
What was the outcome for Zuneca Pharmaceutical? | Zuneca was declared a prior user in good faith and was protected from liability for trademark infringement, but it could not transfer or assign the mark independently of its business. |
What was the outcome for Natrapharm, Inc.? | Natrapharm was affirmed as the lawful registrant of the “ZYNAPSE” mark under the IP Code, solidifying its rights as the registered trademark owner. |
What steps were ordered to prevent confusion between the two medicines? | Both companies were ordered to indicate on their packaging, in plain language, the medical conditions that their respective drugs treat and a warning indicating what each drug is not supposed to treat. |
What future action was required of the Food and Drug Administration? | The Food and Drug Administration was directed to monitor the parties’ compliance with the labeling directives and to take action toward better regulation of pharmaceutical brands. |
This case highlights the importance of trademark registration under the IP Code while also protecting businesses that have previously and in good faith, been using the disputed trademark. It is a balancing act intended to promote both the protection of IP rights and fair competition. This decision underscores the need for businesses to register their trademarks to secure their rights, but it also ensures that prior good-faith users are not unfairly penalized.
For inquiries regarding the application of this ruling to specific circumstances, please contact ASG Law through contact or via email at frontdesk@asglawpartners.com.
Disclaimer: This analysis is provided for informational purposes only and does not constitute legal advice. For specific legal guidance tailored to your situation, please consult with a qualified attorney.
Source: ZUNECA PHARMACEUTICAL v. NATRAPHARM, INC., G.R. No. 211850, September 08, 2020